Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-7b4681f061a21ab4a530ac7b9667ac82",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-7b4681f061a21ab4a530ac7b9667ac82",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-7b4681f061a21ab4a530ac7b9667ac82",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-7b4681f061a21ab4a530ac7b9667ac82\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-7b4681f061a21ab4a530ac7b9667ac82</b></p><a name=\"composition-en-7b4681f061a21ab4a530ac7b9667ac82\"> </a><a name=\"hccomposition-en-7b4681f061a21ab4a530ac7b9667ac82\"> </a><a name=\"composition-en-7b4681f061a21ab4a530ac7b9667ac82-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1772/001-025</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - elucirem</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1772/001-025"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp7b4681f061a21ab4a530ac7b9667ac82"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - elucirem",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Elucirem is and what it is used for</li><li>What you need to know before you are given Elucirem</li><li>How Elucirem will be given to you</li><li>Possible side effects</li><li>How to store Elucirem</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What elucirem is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What elucirem is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Elucirem is a contrast agent which enhances the contrast of the images obtained during magnetic resonance imaging (MRI) examinations. Elucirem contains the active substance gadopiclenol.</p><p>It improves the visualisation and delineation of abnormal structures or lesions of certain parts of the body and helps in the differentiation between healthy and diseased tissue.<br/>It is used in adults and children (2 years of age and older).</p><p>It is given as an injection into your vein. This medicine is for diagnostic use only and will only be administered by healthcare professionals experienced in the field of clinical MRI practice.</p></div>"
}
},
{
"title" : "2. What you need to know before you take elucirem",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take elucirem"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Elucirem must not be given to you</p><ul><li>if you are allergic to gadopiclenol or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor, radiologist or pharmacist before you are given Elucirem:</p><ul><li>if you had a previous reaction to any contrast agent,</li><li>if you have asthma,</li><li>if you have a history of allergy (such as hay fever, hives),</li><li>if your kidneys do not work properly,</li><li>ifyou had seizures (fits) or are being treated for epilepsy,</li><li>if you have a disease affecting your heart or your blood vessels.</li></ul><p>In all these cases, your doctor will decide whether the intended examination is possible or not. If you are given Elucirem, your doctor or radiologist will take the necessary precautions and the administration of it will be carefully monitored.</p><p>Your doctor or radiologist may decide to take a blood test to check how well your kidneys are working before making the decision to use Elucirem, especially if you are 65 years of age or older.</p><p>Other medicines and Elucirem Tell your doctor, radiologist or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, please inform your doctor, radiologist or pharmacist if you are taking or have recently taken medicines for heart and blood pressure disorders such as beta-blocking agents, vasoactive substances, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists.</p><p>Pregnancy and breast-feeding</p><p>Pregnancy Tell your doctor or radiologist if you think you are, or might become pregnant as Elucirem should not be used during pregnancy unless strictly necessary.</p><p>Breast-feeding Tell your doctor or radiologist if you are breast-feeding or about to start breast-feeding.<br/>Your doctor will discuss whether you should continue or interrupt breast-feeding for a period of 24 hours after you receive Elucirem.</p><p>Driving and using machines Elucirem has no or negligible effect on the ability to drive and use machines. However, if you feel unwell after the examination, you should not drive or use machines.</p><p>Elucirem contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 15 mL vial, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take elucirem",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take elucirem"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Elucirem will be injected into your vein using a small needle by a specialised healthcare professional. It can be administered by hand or by an automatic injector.</p><p>Your doctor or radiologist will determine the dose you will receive and supervise the injection. The usual dose of 0.1 mL/kg body weight is the same in adults and children of 2 years and older.</p><p>In children, your doctor or radiologist will use Elucirem in vials with a single use syringe to be able to have a better precision of the injected volume.</p><p>After the injection, you will be kept under supervision for at least 30 minutes. This is the time where most undesired reactions (such as allergic reactions) may occur. However, in rare cases, reactions may occur after hours or days.</p><p>Use in patients with severe kidney problems The use of Elucirem is not recommended in patients with severe kidney problems. However, if it is required you should only receive one dose of Elucirem during a scan and you should not receive a second injection for at least 7 days.</p><p>Use in elderly It is not necessary to adjust your dose if you are 65 years of age or older, but you may have a blood test to check how well your kidneys are working.</p><p>If you receive more Elucirem than you should</p><p>It is highly unlikely that you will receive an overdose of Elucirem, as it will be given to you by a trained healthcare professional. If it does happen, Elucirem can be removed from the body by haemodialysis (blood cleaning).</p><p>If you have any further questions on the use of this medicine, ask your doctor, radiologist or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>After the administration of Elucirem, you will be kept under observation. Most side effects occur within minutes. There is a small risk that you may have an allergic reaction to it. These effects can occur immediately and up to seven days after the injection. Such reactions can be severe and result in shock (case of allergic reaction that could put your life in danger).</p><p>Tell your doctor, radiologist or health professional immediately if you get any of the following side effects as it may be the first signs of a shock:</p><ul><li>swelling of the face, lips, tongue or throat</li><li>lightheadedness (low blood pressure)</li><li>breathing difficulties</li><li>skin rash</li><li>coughing, sneezing or runny nose</li></ul><p>Possible side effects which have been observed during clinical trials with Elucirem are listed below by how likely they are:</p><p>Frequency<br/>Possible side effects<br/>Common (may affect up to 1 in 10 people)<br/>Injection site reaction* Headache Uncommon<br/>(may affect up to 1 in 100 people)<br/>Allergic reaction** Diarrhoea Nausea (feeling sick) Fatigue (tiredness) Abdominal pain Unusual taste in the mouth Feeling of warmth Vomiting (being sick) *Injection site reaction includes: pain, swelling, cold feeling, warm feeling, bruising or redness.<br/>**Allergic reaction may include: inflammation of the skin, reddening of the skin, breathing difficulties, voice impairment, throat tightness, throat irritation, abnormal sensation in the mouth, transient reddening of the face (early reactions) and puffy eyes, swelling, rash and itching (late reactions).</p><p>There have been reports of nephrogenic systemic fibrosis (NSF) (which causes hardening of the skin and may affect also soft tissue and internal organs) with other contrast agent containing gadolinium however no NSF case has been reported with Elucirem during the clinical trials.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store elucirem",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store elucirem"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the vial or pre-filled syringe label and the carton box after EXP . The expiry date refers to the last day of that month.</p><p>This medicine is a clear, colorless to pale yellow solution. Do not use this medicine if the solution is not clear or if it contains visible particles.</p><p>For vials: This medicine does not require any special storage conditions. Chemical and physical in-use stability has been demonstrated for 24 hours at up to 25 C. From a microbiological point of view, the product should be used immediately after opening.</p><p>For pre-filled syringes: Do not freeze.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Elucirem contains</p><ul><li>The active substance is gadopiclenol. Each mL of solution contains 485.1 mg gadopiclenol (equivalent to 0.5 mmol of gadopiclenol and to 78.6 mg of gadolinium).</li><li>The other ingredients are tetraxetan, trometamol, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment) and water for injections. See section 2 Elucirem contains sodium</li></ul><p>What Elucirem looks like and contents of the pack</p><p>It is a clear, colourless to pale yellow solution for injection.</p><p>It is available in packs including:</p><ul><li>1 vial containing 3, 7.5, 10, 15, 30, 50 or 100 mL of solution for injection.</li><li>25 vials containing 7.5, 10 or 15 mL of solution for injection.</li><li>1 or 10 (10 x 1) pre-filled syringes containing 7.5, 10 or 15 mL of solution for injection.</li><li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for manual injection (one extension line and one catheter).</li><li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for Optistar Elite injector (one extension line, one catheter and one empty 60 mL-plastic syringe).</li><li>1 pre-filled syringe containing 7.5, 10 or 15 mL of solution for injection with administration set for Medrad Spectris Solaris EP injector (one extension line, one catheter and one empty 115 mL- plastic syringe).</li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Guerbet 15 rue des Vanesses 93420 Villepinte France</p><p>Manufacturer Guerbet</p><p>16 - 24 rue Jean Chaptal 93600 Aulnay-sous-Bois France</p><p>This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp7b4681f061a21ab4a530ac7b9667ac82",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp7b4681f061a21ab4a530ac7b9667ac82",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp7b4681f061a21ab4a530ac7b9667ac82\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp7b4681f061a21ab4a530ac7b9667ac82</b></p><a name=\"mp7b4681f061a21ab4a530ac7b9667ac82\"> </a><a name=\"hcmp7b4681f061a21ab4a530ac7b9667ac82\"> </a><a name=\"mp7b4681f061a21ab4a530ac7b9667ac82-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1772/001-025</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Elucirem 0.5 mmol/mL solution for injection</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1772/001-025"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Elucirem 0.5 mmol/mL solution for injection",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
